A Potential New Treatment For Rapidly Worsening COVID-19 Patients

Izana Bioscience is a biopharmaceutical company focused on the development of namilumab (IZN-101), an anti-GM-CSF monoclonal antibody in development for the treatment of COVID-19 & rheumatoid arthritis.

About Us

We are a translational medicine company focused on bringing innovative science to market. We are developing a monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte macrophagecolony stimulating factor (GM-CSF).

IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress.

IZN-101 is also in development for the treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), a debilitating arthritic disease with no cure. IZN-101 has demonstrated its efficacy in a Phase IIb study in RA (NEXUS) and is a potential novel treatment, with a novel mode of action.

Clinical Trial

Izana Bioscience has initiated a two-centre compassionate use study of IZN-101 for the treatment of individual patients with rapidly worsening COVID-19 infection.

Development plans for a Phase III study of IZN-101 in rheumatoid arthritis are underway following conclusion of the NEXUS study, with intentions of initiating the trials in the near-term.

Investors and Collaborators

Izana Bioscience has partners who share our commitment to developing IZN-101 for the benefit of patients


Our Team

Izana Bioscience is led by an experienced management team and supported by a world class clinical advisory board

Prof. Bryan Morton CBE

Founded EUSA Pharma - sold to Jazz Pharmaceuticals for $700m
Founded Zeneus Pharma - sold to Cephalon for $360m
Read more

Dr. Someit Sidhu

Chief Executive Officer
BM BCh, Oxon
McKinsey & Company, Pharmaceuticals and Medical Products practice
Read more

Dr. Tim Corn

Chief Medical Officer
Former CMO of EUSA Pharma & Zeneus
Former Senior Executive Elan, GSK
More than 20 regulatory approvals in US and EU
Read more

Contact Us

Send us an email using the form and one of the team will be in touch with you soon.

Please enter your name.
Please enter a valid phone number.
Please enter a message.